Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) shares traded -6.22% lower at $0.43 on Wall Street last session.
In accordance with the data, 3 analysts cover Aeglea BioTherapeutics Inc. (NASDAQ:AGLE). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $6.00 and a low of $0.35, we find $3.18. Given the previous closing price of $0.46, this indicates a potential upside of 591.3 percent. AGLE stock price is now 127.18% away from the 50-day moving average and -5.02% away from the 200-day moving average. The market capitalization of the company currently stands at $32.44M.
It has been rated a hold by 2 analysts and a buy by 1. Brokers who have rated the stock have averaged $3.18 as their price target over the next twelve months.
With the price target of $12, Piper Sandler recently initiated with Overweight rating for Aeglea BioTherapeutics Inc. (NASDAQ: AGLE).
In other news, Souza Marcio, Director bought 90,000 shares of the company’s stock on Aug 25. The stock was bought for $50,472 at an average price of $0.56. Upon completion of the transaction, the Director now directly owns 90,000 shares in the company, valued at $38700.0. A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in AGLE stock. A new stake in Aeglea BioTherapeutics Inc. shares was purchased by CARLYLE GROUP INC. during the first quarter worth $103,000. JANE STREET GROUP, LLC invested $18,000 in shares of AGLE during the first quarter. In the first quarter, VIRTU FINANCIAL LLC acquired a new stake in Aeglea BioTherapeutics Inc. valued at approximately $8,000. In total, there are 71 active investors with 78.80% ownership of the company’s stock.
Aeglea BioTherapeutics Inc. (NASDAQ: AGLE) opened at $0.4800 on Wednesday. During the past 12 months, Aeglea BioTherapeutics Inc. has had a low of $0.11 and a high of $1.56. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 3.50, and a quick ratio of 3.50. The fifty day moving average price for AGLE is $0.1945 and a two-hundred day moving average price translates $0.4523 for the stock.
The latest earnings results from Aeglea BioTherapeutics Inc. (NASDAQ: AGLE) was released for Mar, 2023. The company reported revenue of $0.2 million for the quarter, compared to $1.36 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -85.46 percent.
Aeglea BioTherapeutics Inc.(AGLE) Company Profile
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company’s therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
